Table 2.
Clinical and laboratorial data in three children with Hb SD-Punjab and response to hydroxyurea.
| Id/gender | Age (years) at start of HU | Clinical indication for HU | Dose (mg/kg/day) | Duration (months) | Before hydroxyurea |
After hydroxyurea |
Decreased number of clinical events | ||
|---|---|---|---|---|---|---|---|---|---|
| Total Hb (g/dL)/Hb F (%) | Ret (%) | Total Hb (g/dL)/Hb F (%) | Ret (%) | ||||||
| 11/M | 14 | Severe vaso-occlusive pain episodes | 20 | 8 | 9.5/26.7 | 6.1 | 11.1/34 | 0.4 | Yes |
| 9/M | 6.6 | Severe vaso-occlusive pain episodes | 27 | 76 | 8.5/9.0 | 8.4 | 10.2/17 | 3.4 | Yes |
| 4/Ma | 0.8 | Anemia | 15 | 36 | |||||
| 8 | Severe vaso-occlusive pain episodes | 26 | 27 | 7.6/4.0 | 11.7 | 8.8/20 | 6.3 | Yes | |
Id: identification refers to numbers in Table 1; HU: hydroxyurea; Ret: reticulocyte count.
a
This child was given hydroxyurea in August 2005 because of Hb < 5.0 g/dL. Hydroxyurea was withdrawn in July 2008 by his mother, not by the hematologist. The drug was restarted in September 2012, because of multiple episodes of vaso-occlusive pain.